Cancer immunotherapy: moving forward with peptide T cell vaccines

Current Opinion in Immunology

Volumn 47, Issue , 2017, Pages 57-63

  Kumai, Takumi ^a,b   Fan, Aaron ^a   Harabuchi, Yasuaki ^b   Celis, Esteban ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ALUMINUM POTASSIUM SULFATE; ANTIGEN; BIVAX; CARBOXYMETHYLCELLULOSE; CD40 LIGAND MONOCLONAL ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; EPITOPE; FREUND ADJUVANT; INTERFERON INDUCED HELICASE C DOMAIN CONTAINING PROTEIN 1; PEPTIDE; PEPTIDE VACCINE; POLYINOSINIC POLYCYTIDYLIC ACID; POLYLYSINE; PROTEIN; PROTEIN E7; T CELL VACCINE; UNCLASSIFIED DRUG; CANCER VACCINE; IMMUNOLOGICAL ADJUVANT; SUBUNIT VACCINE; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER THERAPY; CELLULAR IMMUNITY; DRUG EFFICACY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; NONHUMAN; REVIEW; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; ADOPTIVE IMMUNOTHERAPY; ANIMAL; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; NEOPLASM; PROCEDURES; TRANSPLANTATION; TUMOR ESCAPE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; NEOPLASMS; PEPTIDES; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; VACCINES, SUBUNIT;

EID: 85024864255     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2017.07.003     Document Type: Review

References (50)

1. Ahmadzadeh, M., Johnson, L.A., Heemskerk, B., Wunderlich, J.R., Dudley, M.E., White, D.E., Rosenberg, S.A., Tumor antigen-specific CD8T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114 (2009), 1537–1544 This study showed that the majority of tumor-infiltrating T lymphocytes that express PD-1, are functionally impaired.
2. Andersen, R., Donia, M., Ellebaek, E., Borch, T.H., Kongsted, P., Iversen, T.Z., Holmich, L.R., Hendel, H.W., Met, O., Andersen, M.H., et al. Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen. Clin Cancer Res 22 (2016), 3734–3745 This study demonstrated that adoptively transferred T lymphocytes effectively diminished tumor growth in humans.
3. Pico de Coaña, Y., Choudhury, A., Kiessling, R., Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system. Trends Mol Med 21 (2015), 482–491.
4. Sharma, P., Retz, M., Siefker-Radtke, A., Baron, A., Necchi, A., Bedke, J., Plimack, E.R., Vaena, D., Grimm, M.O., Bracarda, S., et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol, 2017.
5. Akbay, E.A., Koyama, S., Carretero, J., Altabef, A., Tchaicha, J.H., Christensen, C.L., Mikse, O.R., Cherniack, A.D., Beauchamp, E.M., Pugh, T.J., et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 3 (2013), 1355–1363.
6. Klein, G., Tumor-specific transplantation antigens: G.H.A. Clowes memorial lecture. Cancer Res 28 (1968), 625–635 Classic work and accomplishments by one of the pioneers in tumor immunology vaccination.
7. Scheffer, S.R., Nave, H., Korangy, F., Schlote, K., Pabst, R., Jaffee, E.M., Manns, M.P., Greten, T.F., Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int J Cancer 103 (2003), 205–211 This paper describes how not all modes of tumor cell death are immunogenic.
8. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D., Mulligan, R.C., Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 90 (1993), 3539–3543 Preclinical data that resulted in the development of GVAX vaccines (Refs. [9–12]).
9. Small, E., Demkow, T., Gerritson, W., Rolland, R., Hoskin, P., Smith, D., Parker, C., Chondros, D., Ma, J., Hege, K., A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel vs. docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). ASCO GU, 2009.
10. Gupta, R., Emens, L.A., GM-CSF-secreting vaccines for solid tumors: moving forward. Discov Med 10 (2010), 52–60.
11. Higano, C., Saad, F., Somer, B., Curti, B., Petrylak, D., Drake, C., Schnell, F., Redfern, D., Schrijvers, D., Sacks, N., A phase III trial of GVAX immunotherapy for prostate cancer vs. docetaxel plus prednisone in asymptomatic castration-resistant prostate cancer (CRPC). ASCO GU, 2009.
12. Salgia, R., Lynch, T., Skarin, A., Lucca, J., Lynch, C., Jung, K., Hodi, F.S., Jaklitsch, M., Mentzer, S., Swanson, S., et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol 21 (2003), 624–630.
13. Castle, J.C., Kreiter, S., Diekmann, J., Lower, M., van de Roemer, N., de Graaf, J., Selmi, A., Diken, M., Boegel, S., Paret, C., et al. Exploiting the mutanome for tumor vaccination. Cancer Res 72 (2012), 1081–1091 This paper identified somatic point mutations in B16 mouse melanoma and showed induction of anti-tumor T cell responses after epitope vaccination.
14. Karosiene, E., Lundegaard, C., Lund, O., Nielsen, M., NetMHCcons: a consensus method for the major histocompatibility complex class I predictions. Immunogenetics 64 (2012), 177–186.
15. Paul, S., Sidney, J., Sette, A., Peters, B., TepiTool: a pipeline for computational prediction of T cell epitope candidates. Curr Protoc Immunol, 114, 2016 18.19.11–18.19.24.
16. Buus, S., Sette, A., Colon, S.M., Miles, C., Grey, H.M., The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides. Science 235 (1987), 1353–1358.
17. Yadav, M., Jhunjhunwala, S., Phung, Q.T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T.K., Fritsche, J., Weinschenk, T., et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515 (2014), 572–576 Very powerful approach to demonstrate the presence of mutated peptides bound to the tumor MHC molecules.
18. Kawashima, I., Tsai, V., Southwood, S., Takesako, K., Sette, A., Celis, E., Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells. Cancer Res 59 (1999), 431–435 Example of the predictive approach to identify and validate T cell epitopes for CTLs.
19. Kobayashi, H., Celis, E., Peptide epitope identification for tumor-reactive CD4T cells. Curr Opin Immunol 20 (2008), 221–227 Review describing predictive approach for identifying HTL epitopes and correlates the presence of proximal or imbedded CTL epitopes.
20. Cho, H.I., Celis, E., Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects. Cancer Res 69 (2009), 9012–9019 Description of the TriVax approach to generate vast CTL responses using peptide, poly-IC and anti-CD40 antibodies.
21. Kumai, T., Lee, S., Cho, H.I., Sultan, H., Kobayashi, H., Harabuchi, Y., Celis, E., Optimization of peptide vaccines to induce robust antitumor CD4 T-cell responses. Cancer Immunol Res, 2016 This study demonstrated that the combination of synthetic peptide, TLR7 ligand, CD40 agonist, and OX40 agonist elicits a huge number of antitumor CD4T lymphocytes with cytotoxic activity.
22. Schurich, A., Pallett, L.J., Lubowiecki, M., Singh, H.D., Gill, U.S., Kennedy, P.T., Nastouli, E., Tanwar, S., Rosenberg, W., Maini, M.K., The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8T cells. PLoS Pathog, 9, 2013, e1003208.
23. Curtsinger, J.M., Lins, D.C., Mescher, M.F., Signal 3 determines tolerance versus full activation of naive CD8T cells: dissociating proliferation and development of effector function. J Exp Med 197 (2003), 1141–1151.
24. Kumagai, Y., Akira, S., Identification and functions of pattern-recognition receptors. J Allergy Clin Immunol 125 (2010), 985–992.
25. Schoenberger, S.P., Toes, R.E., van der Voort, E.I., Offringa, R., Melief, C.J., T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393 (1998), 480–483 Classic paper demonstrating the importance of CD40 ligation in the generation of effective CTL responses.
26. Ahonen, C.L., Doxsee, C.L., McGurran, S.M., Riter, T.R., Wade, W.F., Barth, R.J., Vasilakos, J.P., Noelle, R.J., Kedl, R.M., Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med 199 (2004), 775–784 First report of a peptide vaccine producing a substantial T cell response by combining the antigen with TLR ligand and anti-CD40 antibodies.
27. Curtsinger, J.M., Valenzuela, J.O., Agarwal, P., Lins, D., Mescher, M.F., Type I IFNs provide a third signal to CD8T cells to stimulate clonal expansion and differentiation. J Immunol 174 (2005), 4465–4469.
28. Kohlmeier, J.E., Cookenham, T., Roberts, A.D., Miller, S.C., Woodland, D.L., Type I interferons regulate cytolytic activity of memory CD8(+) T cells in the lung airways during respiratory virus challenge. Immunity 33 (2010), 96–105.
29. Rosenberg, S.A., Yang, J.C., Restifo, N.P., Cancer immunotherapy: moving beyond current vaccines. Nat Med 10 (2004), 909–915 This controversial paper discusses and questions whether cancer vaccines will work against established tumors.
30. Markovic, S.N., Suman, V.J., Ingle, J.N., Kaur, J.S., Pitot, H.C., Loprinzi, C.L., Rao, R.D., Creagan, E.T., Pittelkow, M.R., Allred, J.B., et al. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization. Am J Clin Oncol 29 (2006), 352–360.
31. Legat, A., Maby-El Hajjami, H., Baumgaertner, P., Cagnon, L., Abed Maillard, S., Geldhof, C., Iancu, E.M., Lebon, L., Guillaume, P., Dojcinovic, D., et al. Vaccination with LAG-3Ig (IMP321) and peptides induces specific CD4 and CD8 T-cell responses in metastatic melanoma patients – report of a phase I/IIa clinical trial. Clin Cancer Res 22 (2016), 1330–1340.
32. Barrios, K., Celis, E., TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers. Cancer Immunol Immunother 61 (2012), 1307–1317.
33. Cho, H.I., Barrios, K., Lee, Y.R., Linowski, A.K., Celis, E., BiVax: a peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses. Cancer Immunol Immunother 62 (2013), 787–799 In this paper we showed that poly-IC is a unique adjuvant for peptide vaccines because it stimulates both TLR3 and MDA5.
34. Takeuchi, O., Akira, S., MDA5/RIG-I and virus recognition. Curr Opin Immunol 20 (2008), 17–22.
35. Bijker, M.S., van den Eeden, S.J., Franken, K.L., Melief, C.J., Offringa, R., van der Burg, S.H., CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol 179 (2007), 5033–5040 These authors are proponents of using elongated peptides and avoiding minimal peptide epitopes in vaccines.
36. Kumai, T., Matsuda, Y., Ohkuri, T., Oikawa, K., Ishibashi, K., Aoki, N., Kimura, S., Harabuchi, Y., Celis, E., Kobayashi, H., c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma. Oncoimmunology, 4, 2015, e976077.
37. Mumberg, D., Monach, P.A., Wanderling, S., Philip, M., Toledano, A.Y., Schreiber, R.D., Schreiber, H., CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci U S A 96 (1999), 8633–8638 Interesting and important report showing that HTL recognition of antigen in tumor-infiltrating stromal cells can lead to anti-tumor effects.
38. Sosman, J.A., Sondak, V.K., Melacine: an allogeneic melanoma tumor cell lysate vaccine. Expert Rev Vaccines 2 (2003), 353–368.
39. Li, B., Simmons, A., Du, T., Lin, C., Moskalenko, M., Gonzalez-Edick, M., VanRoey, M., Jooss, K., Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies. Clin Immunol 133 (2009), 184–197.
40. Wei, H., Wang, S., Zhang, D., Hou, S., Qian, W., Li, B., Guo, H., Kou, G., He, J., Wang, H., et al. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice. Clin Cancer Res 15 (2009), 4612–4621.
41. He, X.P., Su, C.Q., Wang, X.H., Pan, X., Tu, Z.X., Gong, Y.F., Gao, J., Liao, Z., Jin, J., Wu, H.Y., et al. E1B-55kD-deleted oncolytic adenovirus armed with canstatin gene yields an enhanced anti-tumor efficacy on pancreatic cancer. Cancer Lett 285 (2009), 89–98.
42. Indraccolo, S., Habeler, W., Tisato, V., Stievano, L., Piovan, E., Tosello, V., Esposito, G., Wagner, R., Uberla, K., Chieco-Bianchi, L., et al. Gene transfer in ovarian cancer cells: a comparison between retroviral and lentiviral vectors. Cancer Res 62 (2002), 6099–6107.
43. Pang, S., Kang, M.K., Kung, S., Yu, D., Lee, A., Poon, B., Chen, I.S., Lindemann, B., Park, N.H., Anticancer effect of a lentiviral vector capable of expressing HIV-1 Vpr. Clin Cancer Res 7 (2001), 3567–3573.
44. Ikonomidis, G., Paterson, Y., Kos, F.J., Portnoy, D.A., Delivery of a viral antigen to the class I processing and presentation pathway by Listeria monocytogenes. J Exp Med 180 (1994), 2209–2218.
45. Echchannaoui, H., Bianchi, M., Baud, D., Bobst, M., Stehle, J.C., Nardelli-Haefliger, D., Intravaginal immunization of mice with recombinant Salmonella enterica serovar Typhimurium expressing human papillomavirus type 16 antigens as a potential route of vaccination against cervical cancer. Infect Immun 76 (2008), 1940–1951.
46. Pan, Y., Li, X., Kang, T., Meng, H., Chen, Z., Yang, L., Wu, Y., Wei, Y., Gou, M., Efficient delivery of antigen to DCs using yeast-derived microparticles. Sci Rep, 5, 2015, 10687.
47. Weber, J.S., Hua, F.L., Spears, L., Marty, V., Kuniyoshi, C., Celis, E., A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma. J Immunother 22 (1999), 431–440.
48. Trimble, C.L., Morrow, M.P., Kraynyak, K.A., Shen, X., Dallas, M., Yan, J., Edwards, L., Parker, R.L., Denny, L., Giffear, M., et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet 386 (2015), 2078–2088.
49. Sebastian, M., Papachristofilou, A., Weiss, C., Fruh, M., Cathomas, R., Hilbe, W., Wehler, T., Rippin, G., Koch, S.D., Scheel, B., et al. Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive(R)) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer, 14, 2014, 748.
50. Shevtsov, M., Multhoff, G., Heat shock protein-peptide and HSP-based immunotherapies for the treatment of cancer. Front Immunol, 7, 2016, 171.